stock decline

Law firm Bragar Eagel & Squire files class action lawsuits against $NAVAN and $COPT alleging material misstatements, citing 60%+ and 50%+ stock declines respectively.

monday.com faces class action lawsuit alleging false growth projections during 2025-2026 period. Stock fell 21% after company abandoned $1.8B 2027 revenue target.

Nokia shares fell 1.14% despite Jefferies' $4.6M institutional position opening, with stock up 19.82% YTD ahead of late April earnings focused on 6G and AI initiatives.

DNOW Inc. shares crashed 19.1% after disappointing Q4 2025 results. The Rosen Law Firm is investigating potential securities violations for investor compensation.

BioNTech shares plummeted as the biotech firm issued lower 2026 revenue guidance and co-founders announced plans to exit by year-end 2026.

CRISPR Therapeutics stock fell 12% after announcing a $350M convertible debt offering. Analysts remain bullish, suggesting the decline may present a buying opportunity.

Law firm investigates $NUTX for securities violations following 24% stock drop tied to $55M arbitration claim reversal affecting nearly 19,000 disputes.

Portnoy Law Firm investigates Encompass Health for securities fraud after New York Times report alleged substandard safety records; stock falls 10.4%.

Law firm launches investigation into $PRCT over alleged securities violations following disappointing earnings report and major revenue guidance cut.

Lakeland Industries faces securities class action alleging CEO and CFO made misleading statements about acquisitions and financial guidance, resulting in shareholder losses.

Securities class action filed against $SNOW alleging officers made materially misleading statements about revenue growth and 2029 targets, triggering 18% stock decline.

Tesla stock has crashed 20% from December highs. Analysts warn the company's 200x forward P/E ratio relies on unrealistic autonomous driving assumptions.

DJS Law Group investigates Olema Pharmaceuticals for potential securities violations following failed Roche trial, triggering sharp stock decline.

Law firm probing Soleno Therapeutics for allegedly concealing safety data on drug DCCR. Investors must file claims by May 5, 2026.

Korn Ferry beats Q3 earnings expectations with $1.28 EPS and $725M sales, while remaining fees backlog rises 11% to $1.9B despite stock decline.

Oracle stock plunged 55% after its $300B OpenAI deal, as massive AI capex ($50B in 2026) and historically weak returns on invested capital raise profitability concerns.

Bath & Body Works faces class action lawsuit alleging failure to disclose that marketing strategy wasn't driving customer growth. Stock fell 24.8% after November miss.

Nu Holdings stock fell 15.6% in February despite 45% revenue growth and 131M customers, as investors fret over U.S. expansion strategy and macroeconomic risks.

$OWLT shares fell 12.95% Monday after issuing weak Q1 2026 guidance of $20-21M versus $26.2M consensus, despite beating Q4 2025 revenue at $26.6M.

GitLab stock has crashed 60% following conservative fiscal 2027 guidance, but now trades at a cheap 3.7x sales multiple amid solid fundamentals.